CN101090706A - Cosmetic or dermatologic composition against dry and/or sensitive skin - Google Patents
Cosmetic or dermatologic composition against dry and/or sensitive skin Download PDFInfo
- Publication number
- CN101090706A CN101090706A CNA2005800371890A CN200580037189A CN101090706A CN 101090706 A CN101090706 A CN 101090706A CN A2005800371890 A CNA2005800371890 A CN A2005800371890A CN 200580037189 A CN200580037189 A CN 200580037189A CN 101090706 A CN101090706 A CN 101090706A
- Authority
- CN
- China
- Prior art keywords
- microorganism
- lactobacillus
- metabolite
- cncm
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
Abstract
The present invention relates to the use of an effective amount of at least one microorganism belonging to the species Lactobacillus paracasei or casei, a fraction thereof or a metabolite thereof, in combination with an effective amount of at least one microorganism belonging to the species Bifidobacterium longum or Bifidobacterium lactis, a fraction thereof or a metabolite thereof, for producing a dermatological composition intended for treating and/or preventing reactive sensitive skin that may or may not be associated with dryness of the skin.
Description
Technical field
What the present invention related generally to concrete microorganism is combined in preparation compositions, especially cosmetics and/or skin composition, more particularly prevents and/or treats the application in the compositions of sensitive skin and/or dry skin.The invention still further relates to corresponding compositions.
Background technology
Usually, sensitive skin is defined by the reactive especially of skin.Yet this reactivity that different with allergic skin is or not to be caused by the immunoreation that the existence of anaphylactogen is made, and promptly should reactivity not occur over just on the skin that becomes responsive.Its mechanism of action is called non-specific.
The reactive of skin shows with the display mode that contacts the uncomfortable signal of having done that can be the triggering element in various sources by individual usually.
Skin reactive usually by individuality to being the display mode performance of the uncomfortable symptom that produced of the triggering element in various sources.Described triggering element can be cosmetics, the food that is absorbed that is applied in the sensitive skin epidermis or make skin under the temperature of sudden change, in the environment that pollutes and/or expose in ultraviolet light or the infrared ray.Also there is correlative factor, for example age and skin properties.Therefore, compare with normal skin, sensitive skin more is common in dry skin or the oily skin.
The uncomfortable symptom of appearance is one of basic feature of sensitive skin in individual several minutes of contacting with the triggering element.Relate generally to dysesthesia (dysesthetic sensations).Term " dysesthesia " is meant the pain perception of feeling at the skin place more or less, for example twinge, tingling, itch or pruritus, burn feeling, burn sense, sense of discomfort, tighten sense etc.These subjective symptoms majorities are lacking visual chemical sex character shape as existing under reddening and peeling.Known at present, these skin irritation are reacted especially with relevant by the neuropeptide that teleneuron discharged of epidermis and corium with intolerance.
Yet the solution that still is not entirely satisfactory so far prevents and/or treats this class sensitive skin, and when sensitive skin was relevant with dry skin, this problem was just more thorny.The feature of dry skin own mainly is to tighten and/or nervous sensation, and its often with the minimizing of moisture of skin and barrier function be damaged relevant, the minimizing of measuring imperceptible water.
Document WO 02/28402 has been described probiotic bacteria can show good effect aspect the skin hypersensitivity that be caused by immunization such as inflammatory reaction and the anaphylaxis regulating, and this is reactive opposite with sensitive skin." Probiotics in the management of atopic eczema; Clinicaland Experimental Allergy 2000 ", Volume 30, pages 1604-1610, the research of mentioning in above-mentioned document has reported that some probiotic bacterias to infant immunization mechanism for example, comprise the individual influences of atopic dermatitis.
Summary of the invention
Outside the expectation, the inventor finds to have at least the combination sensitive skin especially relevant with dry skin to treatment of two specific probiotic bacterias, and is especially effective to the adult.Being combined in as the skin barrier aspect of microorganism of the present invention advantageously shows potential activity, and has special effect aspect the defense function keeping, thereby promoted the adjusting with skin immune system kept of skin-balance.
On the one hand, the present invention relates to the application that preparation is used for preventing and/or treating the compositions of sensitivity and/or dry skin that is combined in that belongs at least a microorganism, its part or its metabolite in bacillus bifidus (Bifidobacteriumlongum) or Bifidobacterium lactis (Bifidobacterium lactis) strain that belongs at least a microorganism, its part or its metabolite and effective dose in Lactobacillus paracasei (Lactobacillusparacasei) or lactobacillus casei (Lactobacillus casei) strain of effective dose.
Therefore, on the other hand, the present invention relates to prevent and/or treat the cosmetic treatment method of sensitivity and/or dry skin, it comprises Lactobacillus paracasei or the bacillus bifidus of at least a microorganism in the lactobacillus casei strain, its part or its metabolite and effective dose or the combination of at least a microorganism in the Bifidobacterium lactis strain, its part or its metabolite of especially oral or external effective dose.
First kind of version, this combination are made into oral absorption with the form of compositions, and it is food supplement or even be exactly food especially.
Second kind of version, according to the present invention, said composition is the form of cosmetics and/or skin composition.
Another aspect the invention still further relates to the cosmetics and/or the skin composition that especially can be used for preventing and/or treating sensitivity and/or dry skin, and it comprises the Lactobacillus paracasei that belongs to of physiologically acceptable carrier, effective dose
ST11 NCC2461 (CNCM I-2116) strainIn the combination that belongs at least a microorganism, its part or its metabolite in bacillus bifidus or the Bifidobacterium lactis strain of at least a microorganism, its part or its metabolite and effective dose.
Again on the one hand, the present invention relates to especially can be used for preventing and/or treating the cosmetics and/or the skin composition of sensitivity and/or dry skin, what it comprised physiologically acceptable carrier, effective dose belongs at least a, its part in Lactobacillus paracasei or the lactobacillus casei strain or the combination that belongs at least a microorganism, its part or its metabolite in bacillus bifidus or the Bifidobacterium lactis strain of its metabolite and effective dose, and
AlsoComprise
At least a bivalent cation
Another aspect, the present invention relates to especially can be used for preventing and/or treating the cosmetics and/or the skin composition of sensitivity and/or dry skin, what it comprised physiologically acceptable carrier, effective dose belongs at least a, its part in Lactobacillus paracasei or the lactobacillus casei strain or the combination that belongs at least a microorganism, its part or its metabolite in bacillus bifidus NCC 490 (CNCM I-2170) or Bifidobacterium lactis NCC2818 (CNCM I-3446) strain of its metabolite and effective dose.
On the other hand, the present invention also relates to a kind of compositions of oral absorption, especially food supplement type, it comprises the combination that belongs at least a microorganism, its part or its metabolite in bacillus bifidus or the Bifidobacterium lactis strain that belongs at least a microorganism, its part or its metabolite and effective dose in Lactobacillus paracasei ST11NCC 2461 (CNCM I-2116) strain of physiologically acceptable carrier, effective dose.
Again on the one hand, the present invention relates to a kind of compositions, especially food supplement type of oral absorption, it comprises belonging to of physiologically acceptable carrier, effective dose
Lactobacillus paracaseiOr
Cheese LactobacillusAt least a, its part in the strain or its metabolite and effective dose belong to bacillus bifidus or
Bifidobacterium lactisThe combination of at least a microorganism in the strain, its part or its metabolite,
AlsoComprise
At least a bivalent cation
Another aspect, the present invention relates to a kind of compositions of oral absorption, especially food supplement type, it comprises the bacillus bifidus that belongs to that belongs at least a, its part in Lactobacillus paracasei or the lactobacillus casei strain or its metabolite and effective dose of physiologically acceptable carrier, effective dose
NCC490 (CNCM I-2170) orBifidobacterium lactis
NCC 2818 (CNCM I-3446)The combination of at least a microorganism in the strain, its part or its metabolite.
Sensitivity and/or dry skin
As mentioned above, different with allergic skin is that the reactivity of sensitive skin is not to be caused by immunoreation, and sensitive skin only shows dysesthesia usually.
Clearly, owing to lack visible symptom, be difficult to sensitive skin is made diagnosis.Usually, this diagnosis is that the patient is being carried out on the basis of inquiring.Semiotics also has the advantage that contact stimulates or allergy is distinguished mutually that allows to relevant with dry skin or incoherent sensitive skin and have visible inflammatory symptom on the other hand.
Therefore, " sensitive skin " Products Development requires to provide and can be used for method that the sensory reaction of skin is assessed.First method, their design come from the basis of fundamental characteristics of sensitive skin, the uncomfortable sign that promptly exists externally applied product to cause.First kind of test of lactic acid " twinge test (stinging test) " therefore, proposed.This test is bestowed 10% lactic acid solution by the wing of nose place to the volunteer, writes down volunteer's twinge sensation then and carries out.The individuality that moderate or strong twinge sensation are experienced in those propositions is called as " twinge person " (stinger), and they are considered to have sensitive skin.Skin based on them is responsive to a kind of external performance of product, selects for use these individualities that " sensitive skin " product is tested thereafter again.Recently, for special activation with uncomfortable relevant and be called the teleneuron of nociceptor (verified recently and sensitive skin is correlated with) and proposed new test, it accurately utilizes for example capsaicin of other uncomfortable evocator.
Another special effective method that sensitive skin is diagnosed is also facilitated in this second kind of test describing in application EP 1374913.
For purposes of the present invention, sensitive skin has been contained irritant skin and intolerance skin.
Intolerance skin is meant multiple factor for example made and applies some make up or skin product or the aitiogenic skin of soap that it is felt as heating, tightens or tingling and/or rubescent.Usually, these symptoms are relevant with the skin of erythema, hyper-seborrhoeaic skin or acne, or even relevant with the skin that shows acne erythematosa (ulcer is arranged or do not have ulcer).
Irritant skin be meant to environment, emotion, food, wind, rub, pick must, hard water, variations in temperature or the aitiogenic skin of woolen various factors of high calcium concentration, show as pruritus, i.e. performance is itched or the sensation of twinge.
Usually, these two kinds of skins can be relevant with the drying property (ulcer is arranged or do not have ulcer) of skin, or relevant with the skin that shows erythema.
As mentioned above, the drying property of skin is usually relevant with the infringement of the moisture minimizing (estimating by humidity of skin) of skin and barrier function, and it is estimated by the loss of measuring imperceptible water.
The base table of dry skin own reveals to be tightened and/or nervous sensation.And the sense of touch of described skin is coarse, presents the covering of squama.When skin is dry a little, a large amount of naked eyes occurs and see distant squama.When situation gets worse, otherwise scale can constantly reduce but naked eyes are seen more obvious.
Body constitution or acquired type may be to cause xerodermatic reason.
In the situation of acquired dry skin, the intervention of extrinsic factor for example contacts chemical reagent, is exposed in extreme climate environment or the sunlight, or accepts some treatment and handle (for example biostearin) and be determiner.Under the influence of these extrinsic factor, it is dry that skin becomes immediately drawn game cloth.Such situation can occur in all kinds of normal skins or even the oily skin.
In the situation of body constitution dry skin, can be divided into two classifications: pathologic skin and non-pathologic skin.
Pathologic body constitution dry skin is representative with heritability dermatitis and ichthyosis substantially.This class skin is irrelevant with external environment in fact.
Heritability dermatitis and cuticular phospholipid, and especially relevant with the metabolic deficiency of ceramide.This pathology itself makes the health major part show more or less chronic axersis, and heritability dermatitis increases severely relevant with inflammatory and prurigo speckle.
Ichthyosis is the pathological characters of genetic defect, and it causes keratinization in different phase.Ichthyosis itself shows by a large amount of speckle decortications occurring.
Non-pathologic body constitution dry skin is meant that its order of severity depends on the skin of the above-mentioned extraneous factor of mentioning.Senile skin (being characterized as metabolic function generally failed with the age), delicate skin (factor very responsive and often have erythema or acne erythematosa to follow) to external world and common xerosis (may be genetic cause, it mainly shows face, extremity and the back of the hand tool) belong to the category of this class skin.
The compositions and methods of the invention are therefore especially effective to preventing and/or treating sensitivity and/or dry skin, and especially effective for reactivity, zest and/or the skin of intolerance, acquired dry skin and/or body constitution dry skin.
Application of the present invention and compositions adopt at least a microorganism that belongs in Lactobacillus paracasei or the lactobacillus casei strain, especially belong to a kind of microorganism in the Lactobacillus paracasei strain, particularly belong to a kind of microorganism in Lactobacillus paracasei ST11 NCC 2461 strains.
More specifically, described microorganism is according to budapest treaty (Treaty of Budapest), be preserved in Institute Pasteur (Pasteur Institute) (28 rue du Docteur Roux-75024Paris Cedex 15), the Lactobacillus paracasei ST11 NCC 2461 of called after CNCM I-2116, or its part or its metabolite.
About belonging to the microorganism in the bifidobacterium species, it can more specifically be selected from bacillus bifidus NCC490 (CNCM I-2170).It is a bacterial strain of being sold called after Bb 536 by MORINAGA.
About belonging to the microorganism in the Bifidobacterium lactis strain, it can more specifically be Bifidobacterium lactis NCC 2818 (CNCM I-3446).
According to a specific embodiment, application of the present invention and compositions adopt Lactobacillus paracasei ST11 NCC 2461 (CNCM I-2116), its part or its metabolite at least, and bacillus bifidus NCC 490 (CNCM I-2170), its part or its metabolite at least.
According to another specific embodiment, application of the present invention and compositions adopt Lactobacillus paracasei ST11 NCC 2461 (CNCM I-2116), its part or its metabolite at least, and Bifidobacterium lactis NCC 2818 (CNCM I-3446), its part or its metabolite at least.
For purposes of the present invention, term " metabolite " means derived from any material in the metabolism of microorganism of the present invention, and described material is also effective to treatment sensitivity and/or dry skin.
For purposes of the present invention, term " part " more specifically means the fragment of described microorganism, and itself and described whole action of microorganisms are similar, and is effective to treatment dryness and/or sensitive skin.
Each corresponding microorganism and/or metabolite and/or part can be mixed with goods in suitable carriers, its ratio is at least 10
3Cfu/g, especially 10
5-10
15Cfu/g, more particularly 10
7-10
12Cfu/g.
According to a version of the present invention, these microorganisms can be made up, as are combined into Lactobacillus paracasei or lactobacillus casei/bacillus bifidus or Lactobacillus paracasei or lactobacillus casei/Bifidobacterium lactis, and its cfu ratio is 0.5-1.5, especially 0.7-1.2, more particularly 1.
Advantageously, application of the present invention and compositions adopt the described microorganism of equivalent at least, and more especially ratio is respectively 10
10The described microorganism of cfu.
These microorganisms can be prepared with pulverulence, i.e. dried forms, or with suspension or the preparation of solution form.
If desired, these microorganisms can be with the form preparation of encapsulation, to improve its time-to-live significantly.In this case, capsule can postpone or stop the degraded of microorganism in gastrointestinal tract especially.
These microorganisms can also be made up with at least a microorganism that belongs to other strains, and described other strains are the strain of probiotic bacteria and/or its part and/or metabolite especially.
For purposes of the present invention, term " probiotic bacteria " means microorganism alive, when it is consumed in right amount, health to the host has positive influences, " joint FAO/WHO Expert Consultationon Evaluation of Health and Nutritional Properties of Probiotic in FoodIncluding Powder Milk with Live Lactic Acid Bacteria; 6 October 2001 ", and it can especially improve the balance of intestinal bacteria.
Be suitable for these microorganisms of the present invention and can specifically be selected from Ascomycetes (ascomycetes), Saccharomyces (Saccharomyces) for example, Ye Luoweiya yeast (Yarrowia), kluyveromyces (Kluyveromyces), spore torulopsis (Torulaspora), schizosaccharomyces pombe (Schizosaccharomyces pombe), Debaryomyces (Debaromyces), candida mycoderma (Candida), Pichia sp. (Pichia), aspergillus (Aspergillus) and penicillium sp (Penicillium), the antibacterial of Bifidobacterium, Bacteroides (Bacteroides), fusobacterium (Fusobacterium), Apis Coccus (Melissococcus), propionibacterium (Propionibacterium), Enterococcus (Enterococcus), Lactococcus (Lactococcus), staphylococcus (Staphylococcus), Peptostrepococcus, bacillus (Bacillus), sheet coccus (Pediococcus), micrococcus luteus (Mirococcus), Leuconostoc (Leuconostoc), Wei Si Bordetella (Weissella), Aerococcus (Aerococcus), drinks wine coccus (Oenococcus) and Lactobacillus (Lactobacillus), with and composition thereof.
For being particularly useful for most Ascomycetes of the present invention, what proposed can be made up of following institute: Candida lipolytica (Yarrowia lipolitica) and Kluyveromyces lactis (Kluyveromyceslactis), and beer yeast (Saccharomyces cereviseae), spore torula (Torulaspora), fragmentation yeast (Schizosaccharamyces pombe), candida mycoderma (Candida) and Pichia sp. (Pichia).
The instantiation of probiotic bacteria is bifidobacterium bifidum (Bifidobacterium bifidum), bifidobacteria infantis (Bifidobacterium infantis), bacillus acidophilus (Lactobacillusacidophilus), nutrition lactobacillus (Lactobacillus alimentarius), lactobacillus curvatus (Lactobacillus curvatus), Deshi Lactobacillus lactic acid subspecies (Lactobacillus delbruckiisubsp.Lactis), lactobacillus gasseri (Lactobacillus gasseri), Lactobacillus johnsonii (Lactobacillus johnsonii), Lactobacillus reuteri (Lactobacillus reuteri), lactobacillus rhamnosus (Lactobacillus rhamnosus, Lactobacillus GG), Lactobacillus saki (Lactobacillus sake), lactococcus lactis (Lactococcus lactis), streptococcus thermophilus (Streptococcus thermophilus), Staphylococccus carnosus and staphylococcus xylosus (Staphylococcus xylosus) with and composition thereof.
More specifically, they are derived from for example being the probiotic bacteria of the lactobacillus of lactobacillus (Lactobacillus) and/or bacillus bifidus (Bifidobacterium).For these lactobacilluss are described, what proposed can more specifically be made up of following institute: Lactobacillus johnsonii, Lactobacillus reuteri, lactobacillus rhamnosus (Lactobacillus rhamnosus), bifidobacterium bifidum, bifidobacterium breve (Bifidobacteriumbreve), animal bifidobacteria (Bifidobacterium animalis), Bifidobacterium lactis, bacillus bifidus, bifidobacteria infantis, bifidobacterium adolescentis (Bifidobacterium adolescentis) or false chainlet bacillus bifidus (Bifidobacterium pseudocatenulatum), with and composition thereof.
The bacterial strain of bacillus bifidus (Bifidobacterium lactis) can (P.O.Box 407 for Chr.HansenA/S, 10-12Boege Aile, and DK-2970 Hoersholm Danemark) obtains product called after Bb 12 from Hansen.
The most especially the strain of Shi Yonging is Lactobacillus johnsonii and bifidobacterium adolescentis and composition thereof.According to budapest treaty, these two strains are deposited in Institute Pasteur (Pasteur Institute) (28 rue duDocteur Roux, F-75024 Paris cedex 15), called after CNCM I-1225 and CNCMI-2168 respectively.
At least a microorganism in will belonging to Lactobacillus paracasei or lactobacillus casei strain is when belonging at least a microorganism in the bifidobacterium species and make up, and application of the present invention or compositions also can be used at least a microorganism that belongs in the Bifidobacterium lactis strain.
Similarly, at least a microorganism in will belonging to Lactobacillus paracasei or lactobacillus casei strain is when belonging at least a microorganism in the Bifidobacterium lactis strain and make up, and application of the present invention or compositions also can be used at least a microorganism that belongs in the bifidobacterium species.
These microorganisms and/or its part and/or its metabolite can be prepared in suitable carriers, and its content is at least 10
3Cfu/g, especially 10
5-10
15Cfu/g, more particularly 10
7-10
12Cfu/g.
What the microorganism in the microorganism formulation of above-mentioned explanation especially was considered is the strain that constitutes combination, and promptly Lactobacillus paracasei or lactobacillus casei, bacillus bifidus and/or Bifidobacterium lactis are the natural above-mentioned microorganisms that is considered that is.
Usually, compositions of the present invention especially Orally administered composition can comprise that amount of viable bacteria is that every gram carrier contains viable count 10
3-10
15Cfu/g, especially 10
5-10
15Cfu/g, more particularly 10
7-10
12Cfu/g; Perhaps, can comprise its equivalent dosage as calculated for inactivated bacteria or dead bacterium or the microorganism part or the metabolite that are produced.Topical composition of the present invention generally includes 10
3Cfu/g, especially 10
5-10
15Cfu/g, more particularly 10
7-10
12The microorganism of cfu/g, especially probiotic bacteria.
When compositions comprised metabolite, the content of metabolite in compositions was basically corresponding to by in every gram carrier 10
3-10
15Cfu, particularly 10
5-10
15Cfu, more especially 10
7-10
12The viable microbial of cfu the amount that can produce.
For Orally administered composition, the concentration of each corresponding microorganism and/or its part and/or its metabolite can be regulated, and makes corresponding to 510
5-10
13Cfu/ day, and particularly 10
8-10
11The dosage of cfu/ day (representing) with corresponding microorganism.
Be included in microorganism in the present composition and can be dead form that live, half activation or deactivation.
Microorganism in the compositions can also be the form of part of cell or the form of metabolite.Microorganism, metabolite or part can also the lyophilized powder forms, culture clear liquid form and/or, be that conc forms is introduced in the time of suitably.
For topical composition, it can advantageously use deactivation or or even the microorganism of dead form.
According to a kind of version of the present invention, application of the present invention and compositions also can adopt one or more bivalence inorganic cations.
In context-descriptive of the present invention, the bivalence inorganic cation can use with various forms.Therefore the bivalence inorganic cation can be inorganic or organic, anhydrous or the form of the complex of hydrated salt or chelating.
These salt can be for example carbonate, bicarbonate, sulfate, glycerophosphate, chloride, nitrate, acetate, hydroxide, oxide, Alpha-hydroxy hydrochlorate (citrate, tartrate, lactate, malate) or fruit hydrochlorate or amino acid salts (aspartate, arginine salt, fumarate) or soap (palmitate, oleate, caseinate, behenate).
According to a specific embodiment, the bivalence inorganic cation is selected from magnesium, copper and/or zinc.
According to another specific embodiment, the bivalence inorganic cation is an alkaline-earth metal.For the spendable alkaline-earth metal of the present invention, mentioned can be made up of barium, calcium, magnesium, strontium and/or beryllium.
Advantageously, be used for especially alkaline-earth metal of bivalence inorganic cation of the present invention, its type of service is a salt.Particularly, described salt can be selected from lime nitrate, strontium nitrate, magnesium gluconate, calcium lactate, gluconic acid strontium, magnesium lactate, calcium chloride, strontium chloride, magnesium chloride, calcium carbonate, strontium sulfate, magnesium sulfate, calcium glycerophosphate, calcium citrate, magnesium citrate, strontium acetate, magnesium acetate with and composition thereof.
According to a concrete favourable embodiment, used at least a bivalence inorganic cation, its be selected from strontium, calcium and/or magnesium citrate, chloride, glucose sugar lime, sulfate, lactate and/or acetate, with and composition thereof.
The complex form of all right chelating of bivalence inorganic cation is used, and especially carries out the complex of chelating with crystal or Ionized albumen.
The bivalence inorganic cation can also be the particular form of being stored by microorganism, for example is the yeast type as selenium yeast.
Therefore, cation can be introduced in the compositions of the present invention with its original form, or the mode of the mixture of at least a above-mentioned cationic known compound by containing high concentration or chemical compound is introduced.For example, as the source of slaine, can use the extract of plant or be rich in cationic yeast.Similarly, calcium also can be introduced by for example milk extract.
The content of the bivalence inorganic cation of use in compositions of the present invention depends on cationic form, and its content can be determined by simple routine experimentation.Every day, dosage can be specially 100 μ g-5g, more specifically was 1mg-2g, or even was 10mg-1.3g.
In the Orally administered composition of the present invention, can regulate the concentration of bivalence inorganic cation, make its corresponding to 1-3000mg/ day, and the dosage of 10-2000mg/ day especially.
Compositions of the present invention is generally external or Orally administered composition.
Compositions of the present invention can be according to the normal any medicament forms that uses of route of administration.
Carrier can be the carrier that meets the various character of types of compositions.
Specially suitable food or pharmaceutical carrier comprise the oral supplement of cereal product, milk powder, child and infant formula, animal foodstuff, especially pet food, tablet or the lozenge of milk, milk fermented product, ice cream, the fermentation of milk, yogurt, cheese, fermentation, liquid bacterium suspension, oral supplement dry product, liquid form.
Particularly, compositions of the present invention can be human edible food compositions.It can specifically be entirely cereal product, ice cream, chocolate, coffee, " cooking " product of dairy products, yogurt, milk powder, enteral nutrition product, child and/or compositions for baby, cereal product or the fermentation of nutraceutical, beverage, mineral water, soup, dietetic supplement and food substitutes, nutrition bar, confection, milk or fermentation, as mayonnaise, tomato soup or salad flavoring agent.Compositions of the present invention also can be used in the animal.
More specifically about cosmetic product, they can be aqueous, water alcohol or oily solution, solution-type dispersion liquid, astringent type dispersion liquid or essence (serum) type dispersion liquid, newborn type emulsion with liquid or semiliquid denseness, the suspension of white type or emulsion, moisture or anhydrous gel, microemulsion, microcapsule, microgranule or ion and/or nonionic steep dispersion liquid more.
For swallowing picked-up, the embodiment of many Orally administered compositions, especially food supplement also are feasible.Prepare dosage form by the conventional method of producing lozenge, gelatine capsule, gel, emulsion, tablet, capsule or solution.Particularly, activating agent of the present invention can mix food supplement or be rich in other any form of food, for example food bar or the powder that presses or the non-powder that presses.Powder can be diluted by water, becomes effervescent beverage(s), milk product or bean product, or powder is mixed in the food bar.
Active substance of the present invention can with conventional excipients that is used for Orally administered composition or food supplement and component, promptly especially in the food manufacturing fats commonly used and/or aqueous components, wetting agent, thickening agent, texture form agent (texturing agent), flavoring agent and/or coating agent, antioxidant, antiseptic and pigment etc. and together carry out preparation.
Be used for Orally administered composition especially required preparation and the excipient of food supplement be known in this area, therefore be not the theme of the detailed description of the invention.
Orally administered composition of the present invention can comprise other several activating agents.
For spendable activating agent, mentioned can be by vitamin B3, B5, B6, B8, C, E or PP, and carotenoid, curcuminoid and nicotinic acid are formed.
Particularly, use and can form by the antioxidant complex, it comprises vitamin C and E, and at least a carotenoid, and concrete carotenoid is selected from beta-carotene, lycopene, 3,4,3',4'-tetraketo-.beta.-carotene (astaxanthine), zeaxanthine and phylloxanthin; Flavonoid is as catechol, Hesperidin, proanthocyanidin and anthocyanin.
Compositions advantageously comprises preceding plain or its mixture of at least a biology.More specifically, element can be selected from oligosaccharide, derivant in glucose, galactose, xylose, maltose, sucrose, lactose, starch, xylan, hemicellulose, inulin, natural gum before these were biological, for example was the arabic gum type, or its mixture.More specifically, oligosaccharide comprises at least a oligofructose.Again particularly, preceding biotin can comprise the mixture of oligofructose and inulin.
The form that relates in particular to cosmetics for external use and/or skin composition can specifically be aqueous, water alcohol or oily solution, solution-type dispersion liquid, astringent type dispersion liquid or essence type dispersion liquid, newborn type emulsion with liquid or semiliquid denseness, fat is dispersed in dispersion liquid (O/W) that aqueous phase obtains or (W/O) conversely mutually, or have the suspension or an emulsion of softness, semisolid or solid denseness, the frost of aqueous gel or anhydrous gel type, or other microemulsion, microcapsule, microgranule or ion and/or nonionic steep dispersion liquid more.
These compositionss prepare according to conventional methods.
These compositionss can specifically be configured for face, hand, foot, main anatomy fold, health cleaning, protection, treatment or nursing usefulness frost (for example; day cream, night frost, makeup removing frost, cream base, sunscreen cream); the product of woman's persona such as end liquid, makeup removing breast or health with protecting breast or nursing breast; shine the back with newborn; skin nursing water, gel or foam; for example cleaning or disinfectant, sun water, artificial solarization Heisui River; bath composition; the deodorant compositions that contains antibacterial; must be back with gel or aftershave lotion, depilatory cream or anti-insect bite compositions.
Compositions of the present invention also can be solid preparation, as soap class or cleaning rod.
Compositions of the present invention also can be used for hair, is the form of aqueous solution, alcohol solution or water-alcohol solution, or the form of frost, gel, emulsion or mousse or contain the form of aerosol compositions of the propellant of compression.
When compositions of the present invention is emulsion, the gross weight of relative compositions, the ratio of fat phase can be 5-80wt%, is preferably 5-50wt%.The employed oil of the compositions of emulsion form, emulsifying agent and co-emulsifier are selected from and are used for the conventional described material that uses of cosmetics and/or skin product field.The gross weight of relative compositions, the emulsifying agent that comprises in the compositions and the ratio of co-emulsifier can be 0.3-30wt%, are preferably 0.5-20wt%.
When compositions of the present invention was oily solution or gel, fat can show mutually greater than 90% of composition total weight.
In known manner, cosmetics of the present invention and/or skin composition also can comprise in cosmetics, medicine and/or the skin product field adjuvant commonly used, for example hydrophilic or lipophilic gel, hydrophilic or lipophilic active agents, antiseptic, antioxidant, solvent, spice, filler, sunscreen, antibacterial, odor absorber and pigment.The consumption of various adjuvants is conventional amount used of this area, for example is the 0.01-20% of compositions gross weight.According to its character, adjuvant can be introduced into fat phase and/or aqueous phase.
For the spendable oils and fats of the present invention, mentioned can be by being formed with following:: mineral oil, freeze as hydrogenant polyisobutylene and liquid petroleum; Vegetable oil is as liquid part, Oleum Helianthi and the almond oil of Adeps Bovis seu Bubali resin; Animal oil is as the perhydro Squalene; Artificial oil, particularly drier oil (Purcellin oil), isopropyl myristate, ethylhexyl cetylate; With contain fluorocarbon oil, as PFPE.Can also utilize: aliphatic alcohol, fatty acid, as stearic acid and wax, as paraffin, Brazil wax and Cera Flava.Can also utilize: polysiloxane compound, as silicone oil, for example cyclomethicone and simethicone, and the wax, resin and the glue that comprise silicone oil.These chemical compounds can be functionalized, also are not functionalized.
For the spendable emulsifying agent of the present invention, mentioned can be made up of following: for example by stearin, polysorbate60, cetearyl alcohol/the contain mixture (commodity that Henkel company the sells Sinnowax AO by name of the oxygen ethylization cetearyl alcohol of 33mol ethylene oxide,1,2-epoxyethane
), the mixture of the PEG-6/PEG-32/ stearic acid two alcohol esters (commodity that Gattefosse company sells Tefose by name
63), PPG-3 Fructus Amomi Rotundus ether, silicone emulsifiers, for example spermaceti dimethyl siloxane polyol (cetyl dimethicone copolyol) and sorbitan monostearate or tristearate, PEG-40 stearate and oxygen ethylization (20 EO) sorbitan monostearate.
For the spendable solvent of the present invention, mentioned can be made up of lower alcohol especially ethanol, isopropyl alcohol and propanol.
Hydrophilic gel for the present invention's use, mentioned can be made up of following institute: the carboxylic acids polymer, as carbomer, acrylic copolymer, for example (commodity that Seppic company sells are called Sepigel 305 to the mixture of acrylate/alkyl acrylate copolymer, polyacrylamide, especially polyacrylamide, the different paraffin of C13-14-and lauryl polyoxyethylene (7) ether
), polysaccharide, for example cellulose derivative, for example hydroxy alkyl cellulose, especially hydroxypropyl cellulose and hydroxyethyl-cellulose, natural gum, for example guar gum, tragon, xanthan gum and clay.
For the lipotropy gel, mentioned can be made up of following: the clay of modification, the slaine of bentonite, fatty acid for example, for example aluminium stearate and hydrophobicity Silicon stone, or ethyl cellulose and polyethylene.
For the hydrophilic activator, employed can the composition: protein or hydrolyzed protein, aminoacid, polyhydric alcohol, especially C by following institute
2-C
10Polyhydric alcohol, as glycerol, sorbitol, butanediol and Polyethylene Glycol, carbamide, allantoin, sugar and sugar derivatives, water soluble vitamins, starch, antibacterial or plant extract are as aloe vera highlights.
For the lipotropy activating agent, employed can the composition by retinol (vitamin A) and derivant, tocopherol (vitamin E) and derivant, ceramide and quintessence oil.
Activating agent of the present invention also can with the activating agent combination that is particularly useful for preventing and/or treating skin disease.
In addition, compositions of the present invention can advantageously comprise spring water and/or mineral water, especially is selected from Vittelwater, from water and the Roche Posay water of Vichy basin.
Cosmetic treatment process of the present invention can especially be incited somebody to action cosmetics and/or skin composition as defined above according to the conventional method of using these compositionss, for example: frost, gel, essence, astringent, makeup removing lotion or solarization back compositions are used for skin or dry hair, to flood and be used for wet hair, the use of the use of shampoo or other classes such as toothpaste.
The using method of cosmetics of the present invention can be by carrying out compositions of the present invention external every day or orally give, combination of the present invention can be made for example following form: gelatine capsule, gel, astringent, lozenge, emulsion, tablet, capsule or oral peace are cutd open, bestow suitable amount and quantity according to its form, make activating agent such as microorganism with every day 510
5To 10
13Cfu, particularly every day 10
6To 10
11The amount of cfu gives, or the equivalent of the microorganism of part deactivation microorganism or dead microorganism or generation part or its metabolite.
According to another embodiment, repetitive administration is 1-3000mg every day until the administered dose of bivalence inorganic cation, and especially every day 10-2000mg.
Using method of the present invention can comprise that single gives.According to another embodiment, for example repeat to give every day 2-3 time, time of application is one day or more, and is generally the long period at least 4 weeks, or even 4-15 week, but a time period of midfeather or a plurality of time period if desired.
In description and following embodiment, unless otherwise mentioned, percentage ratio is weight percentage, and numerical range comprises its upper and lower bound.Before preparation, each composition to be mixed, order by merging and condition are that those skilled in the art determine easily.
The specific embodiment
Following examples are to be used for indefiniteness explanation the field of the invention.
The compositions embodiment of orally give
Embodiment 1: the powder rod
| Active component | |
| Lactobacillus paracasei ST11 NCC 2461 (CNCM I-2116) | 10 10cfu |
| Bacillus bifidus NCC 490 (CNCM I-2170) | 10 10cfu |
| Calcium citrate | 50mg |
| Excipient | |
| Xanthan gum | 0.8mg |
| Sodium benzoate | 0.2mg |
| Maltodextrin | qs 30g |
Take a rod every day.
Embodiment 2: the powder rod
| Active component | |
| Lactobacillus paracasei ST11 NCC 2461 (CNCM I-2116) | 10 10cfu |
| Bacillus bifidus NCC 490 (CNCM I-2170) | 10 10cfu |
| Magnesium citrate | 50mg |
| Excipient | |
| Xanthan gum | 0.8mg |
| Sodium benzoate | 0.2mg |
| Maltodextrin | qs 30g |
Take a rod every day.
Embodiment 3: capsule
| Active component | The mg/ capsule |
| Lactobacillus paracasei ST11 NCC 2461 (CNCM I-2116) | 10 8cfu |
| Bacillus bifidus NCC490 (CNCM I-2170) | 10 8cfu |
| Magnesium gluconate | 150 |
| Vitamin C | 60 |
| Magnesium stearate | 0.02 |
Take one to three capsule every day.
Embodiment 4: the preparation of lozenge
| Active material | The mg/ ingot |
| Magnesium gluconate | 50 |
| Lactobacillus paracasei ST11 NCC 2461 (CNCM I-2116) | 5·10 8cfu |
| Bacillus bifidus NCC 490 (CNCM I-2170) | 5·10 8cfu |
| Calcium citrate | 200 |
| The excipient of lozenge chip | |
| Microcrystalline Cellulose | 70 |
| EncompressTM | 60 |
| Magnesium stearate | 3 |
| Colloidal silica anhydrous | 1 |
| Coating material | |
| Lac | 5 |
| Pulvis Talci | 61 |
| Sucrose | 250 |
| Polyvinylpyrrolidone (polyvidone) | 6 |
| Titanium dioxide | 0.3 |
| Pigment | 5 |
But this lozenge is taken 1-3 time every day.
Embodiment 5: the preparation of lozenge
| Active material | The mg/ ingot |
| Magnesium lactate | 50 |
| Bacillus bifidus NCC 490 (CNCM I-2170) | 10 9cfu |
| Lactobacillus paracasei ST11 NCC 2461 (CNCM I-2116) | 10 9cfu |
| Calcium lactate | 200 |
| The excipient of lozenge chip |
| Microcrystalline Cellulose | 70 |
| Encompress TM | 60 |
| Magnesium stearate | 3 |
| Colloidal silica anhydrous | 1 |
| Coating material | |
| Lac | 5 |
| Pulvis Talci | 61 |
| Sucrose | 250 |
| Polyvinylpyrrolidone (polyvinylidone) | 6 |
| Titanium dioxide | 0.3 |
| Pigment | 5 |
But this lozenge is taken 1-3 time every day.
Embodiment 6: the powder rod
| Active component | |
| Lactobacillus paracasei ST11 NCC 2461 (CNCM I-2116) | 10 10cfu |
| Bifidobacterium lactis NCC 2818 (CNCM I-3446) | 10 10cfu |
| Calcium citrate | 50mg |
| Excipient | |
| Xanthan gum | 0.8mg |
| Sodium benzoate | 0.2mg |
| Maltodextrin | qs 30g |
Can take a rod every day.
Embodiment 7: the powder rod
| Active component | |
| Lactobacillus paracasei ST11 NCC 2461 (CNCM I-2116) | 1010cfu |
| Bifidobacterium lactis NCC 2818 (CNCM I-3446) | 10 10cfu |
| Magnesium citrate | 50mg |
| Excipient | |
| Xanthan gum | 0.8mg |
| Sodium benzoate | 0.2mg |
| Maltodextrin | qs 30g |
Can take a rod every day.
Embodiment 8: capsule
| Active component | The mg/ capsule |
| Lactobacillus paracasei ST11 NCC 2461 (CNCM I-2116) | 10 8cfu |
| Bifidobacterium lactis NCC 2818 (CNCM I-2116) | 10 8cfu |
| Magnesium gluconate | 150 |
| Vitamin C | 60 |
| Magnesium stearate | 0.02 |
Take one to three capsule every day.
Embodiment 9: the prescription of lozenge
| Active substance | The mg/ ingot |
| Magnesium gluconate | 50 |
| Lactobacillus paracasei ST11 NCC 2461 (CNCM I-2116) | 5·10 8cfu |
| Bifidobacterium lactis NCC 2818 (CNCM I-3446) | 5·10 8cfu |
| Calcium citrate | 200 |
| The excipient of lozenge chip | |
| Microcrystalline Cellulose | 70 |
| Encompress TM | 60 |
| Magnesium stearate | 3 |
| Colloidal silica anhydrous | 1 |
| Coating material | |
| Lac | 5 |
| Pulvis Talci | 61 |
| Sucrose | 250 |
| Polyvinylpyrrolidone (polyvidone) | 6 |
| Titanium dioxide | 0.3 |
| Pigment | 5 |
But this lozenge is taken 1-3 time every day.
Embodiment 10: the prescription of lozenge
| Active substance | The mg/ ingot |
| Magnesium lactate | 50 |
| Bifidobacterium lactis NCC 2818 (CNCM I-3446) | 10 9cfu |
| Lactobacillus paracasei NCC 2461 (CNCM I-2116) | 10 9cfu |
| Calcium lactate | 200 |
| The excipient of lozenge chip | |
| Microcrystalline Cellulose | 70 |
| EncompressTM | 60 |
| Magnesium stearate | 3 |
| Colloidal silica anhydrous | 1 |
| Coating material | |
| Lac | 5 |
| Pulvis Talci | 61 |
| Sucrose | 250 |
| Polyvinylpyrrolidone (polyvinylidone) | 6 |
| Titanium dioxide | 0.3 |
| Pigment | 5 |
But this lozenge is taken 1-3 time every day.
Topical composition embodiment
Embodiment 11: the facial astringent of sensitive skin
Lactobacillus paracasei ST11 NCC 2461 (CNCMI-2116) powder 5.00
Bacillus bifidus NCC 490 (CNCM I-2170) powder 5.00
Magnesium gluconate 3.00
Calcium lactate 2.00
Antioxidant 0.05
Isopropyl alcohol 40.0
Antiseptic 0.30
Water qs 100%
Embodiment 12: dryness and sensitive skin facial-care breast
Magnesium chloride 3.00
Calcium ascorbate 3.00
Lactobacillus paracasei ST11 NCC 2461 (CNCM I-2116) powder 5.00
Bacillus bifidus NCC 490 (CNCM I-2170) powder 5.00
Glyceryl stearate 1.00
Cetearyl alcohol/the contain ethylating cetearyl alcohol 3.00 of oxygen of 30mol EO
(the Sinnowax AO that Henkel company sells
)
Spermol 1.00
Simethicone (DC 200 Fluid that Dow Corning company sells
) 1.00
Liquid petroleum peptone 6.00
Isopropyl myristate (the Estol IPM 1514 that Unichema sells
) 3.00
Antioxidant 0.05
Glycerol 20.0
Antiseptic 0.30
Water qs
100
Embodiment 13: sensitive skin facial-care gel
Strontium citrate 4.00
Lactobacillus paracasei ST11 NCC 2461 (CNCM I-2116) powder 5.00
Bacillus bifidus NCC 490 (CNCM I-2170) powder 5.00
Hydroxypropyl cellulose (the Klucel H that Hercules company sells
) 1.00
Vitamin E 2.50
Antioxidant 0.05
Isopropyl alcohol 40.0
Antiseptic 0.30
Water qs
100％
Embodiment 14: dryness and sensitive skin facial-care breast
Magnesium ascorbate 3.00
Seed of black currant oil 4.00
Borage seed oil 4.00
Lactobacillus paracasei ST11 NCC 2461 (CNCM I-2116) powder 5.00
Bacillus bifidus NCC490 (CNCM I-2170) powder 5.00
Glyceryl stearate 1.00
Cetearyl alcohol/the contain ethylating cetearyl alcohol 3.00 of oxygen of 30mol EO
(the Sinnowax AO that Henkel company sells
)
Spermol 1.00
Simethicone (DC 200 Fluid that Dow Coming company sells
) 1.00
Liquid petroleum peptone 6.00
Isopropyl myristate (the Estol IPM 1514 that Unichema company sells
) 3.00
Glycerol 20.0
Antiseptic 0.30
Water qs
100
Embodiment 15: the facial astringent of sensitive skin
Lactobacillus paracasei ST11 NCC 2461 (CNCM I-2116) powder 5.00
Bifidobacterium lactis NCC 2818 (CNCM I-3446) powder 5.00
Magnesium gluconate 3.00
Calcium lactate 2.00
Antioxidant 0.05
Isopropyl alcohol 40.0
Antiseptic 0.30
Water qs 100%
Embodiment 16: dryness and sensitive skin facial-care breast
Magnesium chloride 3.00
Calcium ascorbate 3.00
Lactobacillus paracasei ST11 NCC 2461 (CNCM I-2116) powder 5.00
Bifidobacterium lactis NCC 2818 (CNCM I-3446) powder 5.00
Glyceryl stearate 1.00
Cetearyl alcohol/the contain ethylating cetearyl alcohol 3.00 of oxygen of 30mol EO
(the SinnowaxAO that Henkel company sells
)
Spermol 1.00
Simethicone (DC 200 Fluid that Dow Corning company sells
) 1.00
Liquid petroleum peptone 6.00
Isopropyl myristate (the Estol IPM 1514 that Unichema sells
) 3.00
Antioxidant 0.05
Glycerol 20.00
Antiseptic 0.30
Water qs 100
Embodiment 17: sensitive skin facial-care gel
Strontium citrate 4.00
Lactobacillus paracasei ST11 NCC 2461 (CNCM I-2116) powder 5.00
Bifidobacterium lactis NCC 2818 (CNCM I-3446) powder 5.00
Hydroxypropyl cellulose (the Klucel H that Hercules company sells
) 1.00
Vitamin E 2.50
Antioxidant 0.05
Isopropyl alcohol 40.00
Antiseptic 0.30
Water qs 100%
Embodiment 18: dryness and sensitive skin facial-care breast
Magnesium ascorbate 3.00
Seed of black currant oil 4.00
Borage seed oil 4.00
Lactobacillus paracasei ST11 NCC 2461 (CNCM I-2116) powder 5.00
Bifidobacterium lactis NCC 2818 (CNCM I-2446) powder 5.00
Glyceryl stearate 1.00
(Henkel 3.00 for the ethylating cetearyl alcohol of oxygen of cetearyl alcohol/contain 30mol EO
The commodity that company sells SinnowaxAO by name
)
Spermol 1.00
Simethicone (DC 200 Fluid that Dow Corning company sells
) 1.00
Liquid petroleum peptone 6.00
Isopropyl myristate (the Estol IPM 1514 that Unichema company sells
) 3.00
Glycerol 20.00
Antiseptic 0.30
Water qs 100
Embodiment 19: effect research
Placebo Composition (A) is carried out its measure of merit to xerosis cutis and sensitivity aspect to the Orally administered composition based on probiotic micro-organisms (B) relatively.Separately composed as follows:
A: maltodextrin
B:1 * 10
10The Lactobacillus paracasei ST11 NCC 2461 (CNCM I-2116)+1 * 10 of cfu
10The Bifidobacterium lactis NCC 2818 of cfu (CNCM I-3446)
Therapeutic Method by continue 8 every day in week the orally give single dose form.
66 adult female patients between 18-50 carry out this research to the age, and these women are identified as the patient with dryness and sensitive skin by clinical assessment (clinical score of shank drying property and facial roughness) with by the self assessment (really imitating the sensitive skin questionnaire) of accepting the questionnaire mode.These 66 patients are divided into 2 identical groups, every group 33 people, and the wherein processing of a winding tested person product, and another winding is subjected to the processing of placebo.
By comparing the effect of the supplement that evaluation is tested with contrast " placebo " group.Gained the results are shown in down in the Table I.
Table I
| Relative placebo group, the % significant difference between D1 and the D57 1 | Food supplement (B) based on probiotic bacteria of the present invention |
| Clinical score: be in a ratio of the facial roughness shank aridity of minimizing with D1 | -79％(p＝0.06) -60％(p＝0.02) |
| Self evaluation: be in a ratio of the shank aridity bioanalysis of minimizing with D1: cutaneous sensibility | -28％(p＝0.2) -60％(p＝0.02) |
| Humidity factor: be in a ratio of the carbamide sodium lactate of increase with D1 | The maintenance (p=0.15) of+28% (p=0.6) content is although reduced by 60% than placebo group |
1: the check analysis between treatment group and the placebo group between D1 and the D57.
The Orally administered composition of the embodiment of the invention has carried out testing (cutaneous sensibility being assessed by lactic acid test or twinge test) to the cutaneous sensibility as the patient of this research.
In the patient who receives treatment, viewed cutaneous sensibility has reduced-60% (p=0.02) approximately between D1 and the D57.
Claims (33)
- The bacillus bifidus of at least a microorganism, its part or its metabolite in the Lactobacillus paracasei of effective dose or the lactobacillus casei strain and effective dose or at least a microorganism in the Bifidobacterium lactis strain, its part or its metabolite be combined in that preparation is used for the treatment of and/or prevention and dry skin is relevant or the skin composition of incoherent reactive sensitive skin in application.
- 2. application according to claim 1 is characterized in that, the described microorganism that belongs in Lactobacillus paracasei or the lactobacillus casei strain is microorganism Lactobacillus paracasei ST11 NCC2461 (CNCMI-2116).
- 3. application according to claim 1 and 2 is characterized in that, the described microorganism that belongs in the Bifidobacterium lactis strain is microorganism Bifidobacterium lactis NCC 2818 (CNCM I-3446).
- 4. according to claim 1,2 or 3 described application, it is characterized in that the described microorganism that belongs in the bifidobacterium species is microorganism bacillus bifidus NCC 490 (CNCM I-2170).
- 5. according to aforementioned any described application of claim, it is characterized in that, it uses microorganism Lactobacillus paracasei ST11 NCC 2461 (CNCM 2116), its part or its metabolite at least, and microorganism bacillus bifidus NCC 490 (CNCM I-2170), its part or its metabolite at least.
- 6. according to aforementioned any described application of claim, it is characterized in that, it uses microorganism Lactobacillus paracasei ST11 NCC 2461 (CNCM 2116), its part or its metabolite at least, and microorganism Bifidobacterium lactis NCC 2818 (CNCM I-3446), its part or its metabolite at least.
- 7. according to aforementioned any described application of claim, it is characterized in that described microorganism and/or its part and/or its metabolite can be accepted to be mixed with in the carrier at physiology, its content is at least 10 of carrier 3Cfu/g, especially 10 5-10 15Cfu/g, more particularly 10 7-10 12Cfu/g.
- 8. according to aforementioned any described application of claim, it is characterized in that, described microorganism can be made up, be combined as Lactobacillus paracasei or lactobacillus casei/bacillus bifidus or Lactobacillus paracasei or lactobacillus casei/Bifidobacterium lactis, its cfu ratio is 0.5-1.5, especially 0.7-1.2, more particularly 1.
- 9. according to aforementioned any described application of claim, it is characterized in that it also uses at least a other microorganism, especially probiotic bacteria class and/or its part and/or its metabolite.
- 10. according to aforementioned any described application of claim, it is characterized in that, described microorganism is selected from Saccharomyces, Ye Luoweiya yeast for example, kluyveromyces, the spore torulopsis, schizosaccharomyces pombe, Debaryomyces, candida mycoderma, Pichia sp., aspergillus and penicillium sp, the antibacterial of Bifidobacterium, Bacteroides, fusobacterium, the Apis Coccus, propionibacterium, Enterococcus, Lactococcus, staphylococcus, Peptostrepococcus, bacillus, the sheet coccus, micrococcus luteus, Leuconostoc, the Wei Si Bordetella, Aerococcus, drinks wine coccus and Lactobacillus, with and composition thereof.
- 11. according to claim 9 or 10 arbitrary described application, it is characterized in that, described microorganism is selected from beer yeast, Candida lipolytica, Kluyveromyces lactis, the spore torulopsis, the fragmentation yeast, candida mycoderma, Pichia sp., bifidobacterium bifidum, bifidobacterium breve, animal bifidobacteria, Bifidobacterium lactis, bacillus bifidus, bifidobacteria infantis, bifidobacterium adolescentis, false chainlet bacillus bifidus, the bacillus acidophilus, the nutrition lactobacillus, lactobacillus curvatus, the Deshi Lactobacillus lactic acid subspecies, lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus reuteri, lactobacillus rhamnosus (Lactobacillus GG), Lactobacillus saki, lactococcus lactis, streptococcus thermophilus, Staphylococccus carnosus and staphylococcus xylosus, and composition thereof.
- 12., it is characterized in that described microbial source is in the lactobacillus flora according to any described application of claim 9-11.
- 13., it is characterized in that described microbial source is in Lactobacillus johnsonii (CNCM I-1225), bifidobacterium adolescentis (CNCM I-2168) and composition thereof according to any described application of claim 9-12.
- 14., it is characterized in that it also uses at least a bivalence inorganic cation according to aforementioned any described application of claim.
- 15. application according to claim 14 is characterized in that, described bivalence inorganic cation is an alkaline-earth metal.
- 16. application according to claim 15 is characterized in that, described alkaline-earth metal be selected from barium, calcium, magnesium, strontium, beryllium, and composition thereof.
- 17. application according to claim 16, it is characterized in that, described cation is the form of salt, it is selected from carbonate, bicarbonate, sulfate, glycerophosphate, chloride, nitrate, acetate, hydroxide, oxide, Alpha-hydroxy hydrochlorate for example citrate, tartrate, lactate, malate or fruit hydrochlorate, or amino acid salts such as aspartate, arginine salt, fumarate or soap such as palmitate, oleate, caseinate and behenate.
- 18., it is characterized in that it relates to cosmetic composition according to aforementioned any described application of claim.
- 19., it is characterized in that it relates to food compositions, and especially for human edible compositions according to any described application among the claim 1-17.
- 20., it is characterized in that it relates to skin composition according to any described application among the claim 1-17.
- 21. be used to prevent and/or treat the cosmetic Therapeutic Method of or incoherent sensitive skin relevant with dry skin, it comprises Lactobacillus paracasei or the bacillus bifidus of at least a microorganism in the lactobacillus casei strain, its part or its metabolite and effective dose or the combination of at least a microorganism in the Bifidobacterium lactis strain, its part or its metabolite of oral or external effective dose.
- 22. method according to claim 21 is characterized in that, described microorganism in the claim 2-8 definition.
- 23., it is characterized in that described microorganism and/or its part and/or its metabolite are respectively with 510 according to claim 21 or 22 described methods 5-10 13Cfu/ day, especially 10 8-10 11The administered dose of cfu/ day is used.
- 24. be particularly useful for preventing and/or treating the cosmetics and/or the skin composition of sensitivity and/or dry skin, it comprises the bacillus bifidus of at least a microorganism, its part or its metabolite and effective dose in Lactobacillus paracasei ST11 NCC2461 (CNCM I-2116) strain of the effective dose in the physiologically acceptable carrier or the combination of at least a microorganism in the Bifidobacterium lactis strain, its part or its metabolite.
- 25. be particularly useful for preventing and/or treating the cosmetics and/or the skin composition of sensitivity and/or dry skin, what it comprised effective dose in the physiologically acceptable carrier belongs at least a, its part in Lactobacillus paracasei or the lactobacillus casei strain or the combination that belongs at least a microorganism, its part or its metabolite in bacillus bifidus or the Bifidobacterium lactis strain of its metabolite and effective dose, and also comprises at least a bivalence inorganic cation.
- 26. be particularly useful for preventing and/or treating the cosmetics and/or the skin composition of sensitivity and/or dry skin, it comprises the combination that belongs at least a microorganism, its part or its metabolite in bacillus bifidus NCC 490 (CNCM I-2170) or Bifidobacterium lactis NCC 2818 (CNCM I-3446) strain that belongs at least a microorganism, its part or its metabolite and effective dose in Lactobacillus paracasei or the lactobacillus casei strain of the effective dose in the physiologically acceptable carrier.
- 27. the compositions of oral absorption, it comprises the combination that belongs at least a microorganism, its part or its metabolite in bacillus bifidus or the Bifidobacterium lactis strain that belongs at least a microorganism, its part or its metabolite and effective dose in Lactobacillus paracasei ST11 NCC 2461 (CNCM I-2116) strain of the effective dose in the physiologically acceptable carrier.
- 28. the compositions of oral absorption, it comprises the combination that belongs at least a microorganism, its part or its metabolite in bacillus bifidus or the Bifidobacterium lactis strain that belongs at least a microorganism, its part or its metabolite and effective dose in Lactobacillus paracasei or the lactobacillus casei strain of the effective dose in the physiologically acceptable carrier, and also comprises at least a bivalence inorganic cation.
- 29. the compositions of oral absorption, it comprises the combination that belongs at least a microorganism in bacillus bifidus NCC490 (CNCM I-2170) or the Bifidobacterium lactis NCC 2818CNCM I-3446 strain that belongs at least a microorganism, its part or its metabolite and effective dose in Lactobacillus paracasei or the lactobacillus casei strain of the effective dose in the physiologically acceptable carrier.
- 30. according to any described compositions among the claim 24-29, it is characterized in that, described microorganism in the claim 2-8 definition.
- 31., it is characterized in that it also comprises at least a bivalence inorganic cation according to any described compositions in the claim 24,26,27,29 and 30.
- 32. according to claim 25,28 or 31 described compositionss, it is characterized in that, described bivalence inorganic cation in the claim 14-17 definition.
- 33., it is characterized in that it also comprises at least a as defined microorganism among the claim 9-13 according to any described compositions among the claim 24-32.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0452258 | 2004-10-04 | ||
| FR0452258A FR2876029B1 (en) | 2004-10-04 | 2004-10-04 | COSMETIC AND / OR DERMATOLOGICAL COMPOSITION FOR SENSITIVE SKINS. |
| US63453904P | 2004-12-10 | 2004-12-10 | |
| US60/634,539 | 2004-12-10 | ||
| EP05012301A EP1731137A1 (en) | 2005-06-08 | 2005-06-08 | Cosmetic or dermatologic composition against dry and/or sensitive skin |
| EP05012301.7 | 2005-06-08 | ||
| PCT/FR2005/050807 WO2006037922A1 (en) | 2004-10-04 | 2005-10-03 | Cosmetic and/or dermatological composition for sensitive skins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101090706A true CN101090706A (en) | 2007-12-19 |
| CN101090706B CN101090706B (en) | 2013-05-29 |
Family
ID=34949285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005800371890A Active CN101090706B (en) | 2004-10-04 | 2005-10-03 | Cosmetic or dermatologic composition against sensitive skin |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101090706B (en) |
| FR (1) | FR2876029B1 (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102755281A (en) * | 2012-07-13 | 2012-10-31 | 无锡紫昂生物科技有限公司 | Cosmetic containing microbial modulator |
| CN102858948A (en) * | 2010-01-08 | 2013-01-02 | 热尔韦·达诺尼公司 | Lactobacilli with anti-oxidant action |
| CN103826648A (en) * | 2011-04-15 | 2014-05-28 | 雀巢产品技术援助有限公司 | Lactobacillus paracasei NCC2461 (ST11) for use by perinatal maternal administration in the reduction and prevention of allergies in progeny |
| CN104188888A (en) * | 2009-12-08 | 2014-12-10 | 欧莱雅 | Probiotic microorganisms as an active ingredient for enhancing skin radiance |
| CN102105132B (en) * | 2008-07-29 | 2014-12-10 | 欧莱雅 | Cosmetic use of microorganisms for the treatment of oily skin |
| CN106389176A (en) * | 2016-08-31 | 2017-02-15 | 哈尔滨欧替药业有限公司 | Hydrogel facial mask for private parts |
| CN106727263A (en) * | 2016-11-22 | 2017-05-31 | 深圳弘睿康生物科技有限公司 | Skin Tiny ecosystem improves preparation and preparation method thereof |
| US10238897B2 (en) | 2007-09-04 | 2019-03-26 | L'oreal | Use of a lysate of bifidobacterium species for treating sensitive skin |
| CN110013490A (en) * | 2018-01-09 | 2019-07-16 | 柯顺议 | Probiotic composition and application thereof |
| US11154731B2 (en) | 2007-09-04 | 2021-10-26 | L'oreal | Cosmetic use of Bifidobacterium species lysate for the treatment of dryness |
| CN113768859A (en) * | 2021-06-23 | 2021-12-10 | 仙婷(广州)科技研发有限公司 | Oral and external composition for improving sensitive skin and application thereof |
| CN115093985A (en) * | 2022-04-24 | 2022-09-23 | 深圳市多微生保健食品有限公司 | Bifidobacterium lactis and fermentation method and application thereof |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2920306B1 (en) * | 2007-09-04 | 2010-07-30 | Oreal | COSMETIC USE OF A SPECIFIC BIFIDOBACTERIEUM LYSAT. |
| FR2940908B1 (en) | 2009-01-12 | 2012-08-24 | Oreal | COSMETIC ASSOCIATION OF A MICROORGANISM AND A PHYTOSPHINGOSINE DERIVATIVE |
| FR2942719B1 (en) | 2009-03-04 | 2011-08-19 | Oreal | USE OF PROBIOTIC MICROORGANISMS TO LIMIT SKIN IRRITATION |
| FR2959128B1 (en) * | 2010-04-23 | 2012-07-13 | Oreal | COSMETIC USE OF A SPECIFIC BIFIDOBACTERIUM LYSATE FOR THE TREATMENT OF BODY ODORS |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100302504B1 (en) * | 1998-12-12 | 2001-09-22 | 이세복 | Fermented product using lactic acid bacteria and cosmetic composition |
| KR100324441B1 (en) * | 1999-02-08 | 2002-02-27 | 이은선 | Food for preventing gastritis, gastric and duodenal ulcers |
| KR100351548B1 (en) * | 2000-05-25 | 2002-09-11 | 나드리화장품주식회사 | Conditioning hair-care containing fermented product using lactic acid bacteria |
| FI110668B (en) * | 2000-06-20 | 2003-03-14 | Aboatech Ab Oy | Use of probiotics for primary prevention of atopic diseases |
| ES2263990T3 (en) * | 2002-02-21 | 2006-12-16 | Societe Des Produits Nestle S.A. | ORALLY ADMINISTRABLE COMPOSITION FOR THE PHOTOPROTECTION OF THE SKIN. |
| ES2297181T3 (en) * | 2002-02-21 | 2008-05-01 | Societe Des Produits Nestle S.A. | A PHOTOPROTECTOR COMPOSITION FOR THE SKIN, ORAL ADMINISTRATION. |
| US7179460B2 (en) * | 2002-12-05 | 2007-02-20 | Danisco A/S | Bacterial composition and its use |
-
2004
- 2004-10-04 FR FR0452258A patent/FR2876029B1/en active Active
-
2005
- 2005-10-03 CN CN2005800371890A patent/CN101090706B/en active Active
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10238897B2 (en) | 2007-09-04 | 2019-03-26 | L'oreal | Use of a lysate of bifidobacterium species for treating sensitive skin |
| US11154731B2 (en) | 2007-09-04 | 2021-10-26 | L'oreal | Cosmetic use of Bifidobacterium species lysate for the treatment of dryness |
| CN102105132B (en) * | 2008-07-29 | 2014-12-10 | 欧莱雅 | Cosmetic use of microorganisms for the treatment of oily skin |
| CN104188888A (en) * | 2009-12-08 | 2014-12-10 | 欧莱雅 | Probiotic microorganisms as an active ingredient for enhancing skin radiance |
| CN102858948A (en) * | 2010-01-08 | 2013-01-02 | 热尔韦·达诺尼公司 | Lactobacilli with anti-oxidant action |
| CN102858948B (en) * | 2010-01-08 | 2015-11-25 | 热尔韦·达诺尼公司 | There is the lactobacillus of antioxygenation |
| CN103826648A (en) * | 2011-04-15 | 2014-05-28 | 雀巢产品技术援助有限公司 | Lactobacillus paracasei NCC2461 (ST11) for use by perinatal maternal administration in the reduction and prevention of allergies in progeny |
| CN102755281A (en) * | 2012-07-13 | 2012-10-31 | 无锡紫昂生物科技有限公司 | Cosmetic containing microbial modulator |
| CN106389176A (en) * | 2016-08-31 | 2017-02-15 | 哈尔滨欧替药业有限公司 | Hydrogel facial mask for private parts |
| CN106727263A (en) * | 2016-11-22 | 2017-05-31 | 深圳弘睿康生物科技有限公司 | Skin Tiny ecosystem improves preparation and preparation method thereof |
| CN110013490A (en) * | 2018-01-09 | 2019-07-16 | 柯顺议 | Probiotic composition and application thereof |
| CN113768859A (en) * | 2021-06-23 | 2021-12-10 | 仙婷(广州)科技研发有限公司 | Oral and external composition for improving sensitive skin and application thereof |
| CN115093985A (en) * | 2022-04-24 | 2022-09-23 | 深圳市多微生保健食品有限公司 | Bifidobacterium lactis and fermentation method and application thereof |
| CN115093985B (en) * | 2022-04-24 | 2023-10-20 | 深圳市多微生保健食品有限公司 | Lactobacillus bifidus and fermentation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101090706B (en) | 2013-05-29 |
| FR2876029A1 (en) | 2006-04-07 |
| FR2876029B1 (en) | 2008-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101090706B (en) | Cosmetic or dermatologic composition against sensitive skin | |
| CN1712022B (en) | Process and compositions for the protection and/or the treatment of dry and/or sensitive skin | |
| AU2005291098B2 (en) | Cosmetic and/or dermatological composition for sensitive skins | |
| AU2005257033B2 (en) | Method and compositions useful for preventing and/or treating sensitive and/or dry skin | |
| US11154731B2 (en) | Cosmetic use of Bifidobacterium species lysate for the treatment of dryness | |
| AU2006274792B2 (en) | Cosmetic and/or dermatological composition for prevention and/or treatment of sensitive or dry skin | |
| CN102105132B (en) | Cosmetic use of microorganisms for the treatment of oily skin | |
| US20120301452A1 (en) | Probiotic microorganisms as active agents for enhancing the radiance of the skin's complexion | |
| US20120294841A1 (en) | Probiotic microorganisms as active agents against changes in the skin's microrelief | |
| EP1642570A1 (en) | Cosmetic or dermatologic composition against dry and/or sensitive skin | |
| EP1731137A1 (en) | Cosmetic or dermatologic composition against dry and/or sensitive skin | |
| CA2522717C (en) | Cosmetic and/or dermatological composition for sensitive skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200227 Address after: Fa Guobali Co-patentee after: Societe des Produits Nestle S.A. Patentee after: L'Oreal Address before: Fa Guobali Co-patentee before: Nestec Co., Ltd. Patentee before: L'Oreal |